| |
Univariable HR (95% CI)
|
Multivariablea HR (95% CI) – Overall
|
|---|
|
Tumor type
|
|
GCTs
|
Ref.
|
Ref.
|
|
SCSTs
|
2.96 (2.03–4.33)***
|
1.68 (1.13–2.49)*
|
|
Age (per 5-year increase)
|
1.21 (1.19–1.23)***
|
1.18 (1.16–1.20)***
|
|
Race/ethnicity
|
|
Non-Hispanic White
|
Ref.
|
Ref.
|
|
Non-Hispanic Black
|
1.80 (1.41–2.29)***
|
1.13 (0.89–1.45)
|
|
Hispanic/other
|
1.27 (1.13–1.43)***
|
1.14 (1.01–1.30)*
|
|
Insurance
|
|
Private insurance
|
Ref.
|
Ref.
|
|
Uninsured
|
2.63 (2.29–3.01)***
|
2.32 (2.01–2.66)***
|
|
Medicaid/Medicare/other government insurance
|
4.33 (3.88–4.83)***
|
2.72 (2.42–3.05)***
|
|
Income (per year)
|
|
< $38,000
|
Ref.
|
Ref.
|
|
$38,000–$62,999
|
0.71 (0.62–0.81)***
|
0.94 (0.82–1.09)
|
|
> $63,000
|
0.44 (0.38–0.50)***
|
0.76 (0.63–0.92)**
|
|
Percent in ZIP code without a high school diploma
|
|
> 21%
|
Ref.
|
Ref.
|
|
7–20.9%
|
0.63 (0.56–0.71)***
|
0.83 (0.73–0.96)*
|
|
< 7%
|
0.43 (0.37–0.49)***
|
0.74 (0.61–0.90)**
|
|
Residence
|
|
Metropolitan
|
Ref.
|
Ref.
|
|
Urban/rural
|
1.49 (1.33–1.67)***
|
1.13 (1.00–1.28)
|
|
Charlson-Deyo comorbidity score
|
|
0
|
Ref.
|
Ref.
|
|
≥ 1
|
3.23 (2.82–3.70)***
|
2.06 (1.79–2.37)***
|
- CI Confidence interval, GCTs Germ cell tumors, HR Hazard ratio, IQR Interquartile range, SCSTs Sex cord stromal tumors
- *p < 0.05
- **p < 0.01
- ***p < 0.001
- aThe following variables were included in the multivariable analysis: tumor type, age, diagnosis year, race/ethnicity, insurance, yearly income, percent in ZIP code without a high school diploma, residence, Charlson-Deyo comorbidity score
